Phase 2 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand and are willing to sign a written consent form
- People aged 18 to 80 years old
- People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (confirm with trial site)
- People whose cancer has been confirmed by a tissue or cell sample to be advanced pancreatic adenocarcinoma (a specific type of pancreatic cancer)
- People whose cancer has stopped responding to at least one round of chemotherapy, and who have not previously received radiotherapy
- People whose pancreatic cancer has spread locally or to other parts of the body
- People whose blood test results show that three specific cancer markers (CA19-9, CEA, and CA125) are at or below certain low levels (confirm with trial site)
- People who have at least one tumour that can be measured using standard imaging guidelines
- People whose expected survival is at least 3 months
- People whose liver, kidneys, and other organs are functioning well enough, based on blood tests
- Women who could become pregnant, and men, who agree to use reliable contraception throughout the trial
Who may not be able to join:
- Women who are pregnant or currently breastfeeding
- People whose cancer is a primary pancreatic cancer that has not yet spread (confirm with trial site)
- People whose blood test results show that any of the three cancer markers (CA19-9, CEA, or CA125) are above the specified levels
- People whose cancer has been confirmed by pathology to be a type of pancreatic cancer other than adenocarcinoma
- People who have inflammation in the digestive system, such as pancreatitis, gallbladder inflammation, or bile duct inflammation
- People with severe or uncontrolled other illnesses that could affect how well the trial runs or make results harder to interpret
- People with kidney failure or who are on dialysis
- People with other serious illnesses that, in the treating doctor's opinion, could significantly affect treatment safety
- People who have a known allergy to oxaliplatin or other chemotherapy drugs
- People who are unwilling or unable to follow the trial's required procedures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Guopei Luo, MD, Fudan University
Phone: 86 64175590
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
progression-free survival, PFS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.